Carna Biosciences, Inc. reports consolidated earnings results for the six months ended June 30, 2021. For the six months, on consolidated basis, Net sales were JPY 430 million against JPY 579 million reported a year ago. Operating loss were JPY 777 million against JPY 375 million reported a year ago. Loss were JPY 776 million against JPY 397 million reported a year ago. Basic loss per share was JPY 62.56 against JPY 32.60 reported a year ago.